Bioceres Crop Solutions (BIOX) Cash & Equivalents (2016 - 2026)

Bioceres Crop Solutions has disclosed Cash & Equivalents across 11 years of filings, most recently posting $14.4 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $14.4 million, down 67.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.4 million (down 67.62% YoY), and the FY2025 annual result was $44.5 million, changed 0.0% from the prior year.
• Cash & Equivalents came in at $14.4 million for Q1 2026 at Bioceres Crop Solutions, up from $11.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $68.6 million in Q4 2022 to a low of -$57.7 million in Q1 2023.
• The 5-year median for Cash & Equivalents is $33.5 million (2022), against an average of $20.2 million.
• Peak annual rise in Cash & Equivalents reached 249.34% in 2022, while the deepest fall reached 280.58% in 2022.
• Bioceres Crop Solutions' Cash & Equivalents stood at $68.6 million in 2022, then decreased by 29.79% to $48.1 million in 2023, then retreated by 7.6% to $44.5 million in 2024, then slumped by 75.12% to $11.1 million in 2025, then surged by 30.14% to $14.4 million in 2026.
• The last three Cash & Equivalents figures came in at $14.4 million (Q1 2026), $11.1 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.